Breaking News

Therapure To Fill/Finish for YM MAb

Therapure Biopharma will provide fill and finish services for YM BioSciences' EGFR binder

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Therapure Biopharma will provide fill and finish services for YM BioSciences‘ nimotuzumab, a humanized monoclonal antibody currently being tried against a variety of cancers. Nimotuzumab is licensed to YM’s majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM). Therapure will formulate and fill nimotuzumab into sterile vials in its aseptic GMP-certified and Health Canada-licensed fill suite in Mississauga, Canada. The final product...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters